Print Magazine
Brussels Morning Newspaper
Wednesday, May 18, 2022
No Result
View All Result
  • Home
    • About Us
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Europe With Transparency
    • Sustainable Perspective
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Newspaper
  • Home
    • About Us
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Europe With Transparency
    • Sustainable Perspective
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Newspaper
No Result
View All Result
Home World

Merck seeks US authorization for first Covid tablet treatment

Tom Canetti by Tom Canetti
11 October 2021
in World
Merck seeks US authorization for first Covid tablet treatment
Share on FacebookShare on Twitter

Brussels (Brussels Morning) US pharmaceutical giant Merck has announced it has applied for emergency use authorization for Molnupiravir, its tablet treatment for COVID-19.  If approved by the Food and Drug Administration (FDA), it will be the first oral antiviral medication for treating the virus. 

A clinical trial for mild-to-moderately ill patients with coronavirus showed Molnupiravir cut hospitalisations and death rates by 50%. Merck says the treatment is effective against all strains of the virus, including the Delta variant. The pill could also drastically ease pressure on hospitals and temporary vaccination stations since it can be administered at home.

“Today we took the next step in helping in the fight against COVID-19 by applying for Emergency Use Authorization in the US for our investigational antiviral treatment”, the company announced on Monday. 

“We look forward to working with the FDA on its review of our application.” 

Merck has agreed to licence the treatment to sub-contractors based in India who will supply Molnupiravir to more than 100 less developed countries. However, the pharmaceutical giant is already facing criticism for hefty profit margins.  

Pricing termed “an outrage”

Former US Secretary of Labour Robert Reich said: “The drug costs them less than 18 dollars to produce. They’re [Merck] charging the U.S. government 712 dollars— 40 times the price to produce it.

“Their sales could reach 7 billion dollars by the end of the year.

“An outrage”, he concluded.

Merck says they expect to produce 10 million courses of Molnupiravir by the end of 2021, with a domestic contract of 1.7 million courses solely in the US.

A Harvard study by drug costing experts estimates “the cost of production for Molnupiravir capsules is US$1.74 per unit, or US$17.74 per 5-day regimen.”

“Adding an allowance for 10% profit margin and taxes in India, we arrive at an estimated sustainable generic price of US$1.96 per capsule or US$19.99 per 5-day regimen”, the study states.

The analysis concludes that the price which Merck will sell Molnupiravir for is roughly 35 times the sustainable cost price, which already allows for profit margins and taxes in India.

Nurses, doctors and medical infrastructure have been overwhelmed by evolving mutations of the virus, such as the Delta variant. Molnupiravir could be a key tool in reducing the climbing death toll from COVID. Yet many are questioning so-called pandemic price gouging from pharmaceutical giants profiting off the pandemic.

Tags: Main-SliderWorld-Feature

Latest post

Brussels spells out a plan for closer cooperation with Arab Gulf countries

Brussels spells out a plan for closer cooperation with Arab Gulf countries

50 mins ago
International,Business,Team,Shows,Its,Solidarity

EU member states to support youth employment

4 hours ago

Most Read

  • shutterstock_1821616664

    MEPs send Open Letter urging the Home Secretary Priti Patel to reject Assange’s extradition

    0 shares
    Share 0 Tweet 0
  • These are the 10 highest paying jobs in the Europe in 2022

    0 shares
    Share 0 Tweet 0
  • Why corruption matters

    0 shares
    Share 0 Tweet 0
  • Brussels residents want to set up school for Ukrainian children

    0 shares
    Share 0 Tweet 0
  • Sweden: Taking Syrian children away from parents for protection?

    0 shares
    Share 0 Tweet 0
Facebook Twitter Youtube LinkedIn

About Us

Brussels Morning is a daily online newspaper based in Belgium. BM publishes unique and independent coverage on international and European affairs. With a Europe-wide perspective, BM covers policies and politics of the EU, significant Member State developments, and looks at the international agenda with a European perspective.

Category

  • Ambassador’s Corner
  • Belgium News
  • Brussels
  • Commission
  • Council
  • Culture and Society
  • Diplomacy
  • Economy
  • EU Institutions
  • Europe
  • Europe With Transparency
  • Features
  • In Depth
  • Member States
  • Middle East Eye
  • Opinion
  • Our pick
  • Parliament
  • Place de la Bourse
  • Southeast Europe
  • Sustainable Perspective
  • The American Angle
  • The Macro-Economist
  • Uncategorised
  • US Elections
  • World

More info

  • About Us
  • Advertising
  • Cookies Policy
  • Contact Us
  • FAQ
  • Jobs

Brussels Morning Newspaper - All Rights Reserved © 2020

No Result
View All Result
  • Home
  • About Us
  • EU Institutions
    • Parliament
    • Commission
    • Council
  • Europe
  • World
  • Member States
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • Europe With Transparency
    • Place de la Bourse
    • The Macro-Economist
    • Sustainable Perspective
    • The American Angle
    • Southeast Europe
  • Print Magazine

Brussels Morning Newspaper - All Rights Reserved © 2020

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT